Joel Ackerman Sells 51,471 Shares of DaVita (NYSE:DVA) Stock

DaVita Inc. (NYSE:DVA) CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

DaVita Trading Up 0.6%

DVA stock opened at $200.22 on Wednesday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $202.69. The firm has a market cap of $12.85 billion, a P/E ratio of 18.57, a P/E/G ratio of 0.65 and a beta of 0.84. The business’s 50 day moving average is $155.80 and its 200-day moving average is $134.19.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.DaVita’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts forecast that DaVita Inc. will post 15.07 EPS for the current year.

Institutional Investors Weigh In On DaVita

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in shares of DaVita by 2.0% during the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares in the last quarter. Morgan Stanley increased its position in shares of DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after purchasing an additional 71,156 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in DaVita by 114.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of DaVita by 5.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after purchasing an additional 56,336 shares in the last quarter. Finally, LSV Asset Management increased its position in shares of DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Key DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita’s recent quarter beat expectations, with EPS of $2.87 versus $2.33 expected and revenue of $3.42 billion versus $3.36 billion expected, reinforcing the case for improved operating performance and supporting the stock’s recent strength. Article Title
• Positive Sentiment: Analysts turned more constructive, with Deutsche Bank upgrading the stock to buy and raising its target to $220, while UBS lifted its target to $235; TD Cowen also increased its target to $201. These moves helped push the stock to a fresh 1-year high. Article Title
• Positive Sentiment: Zacks highlighted DaVita as a strong momentum stock and one of its top-ranked growth names, adding to investor enthusiasm around the shares. Article Title
• Positive Sentiment: Commentary from market watchers said operational discipline and technology investments are driving outperformance, which may help investors view the company’s earnings power as improving. Article Title
• Neutral Sentiment: DaVita CFO Joel Ackerman sold 51,471 shares worth about $9.9 million. While insider sales can raise questions, the transaction was disclosed and does not necessarily signal a change in business fundamentals. Article Title

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of research reports. Truist Financial boosted their price objective on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday. UBS Group raised their price objective on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. TD Cowen increased their price objective on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and increased their target price for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus price target of $199.17.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.